FDA — authorised 18 March 2022
- Application: BLA761234
- Marketing authorisation holder: BRISTOL MYERS SQUIBB
- Local brand name: OPDUALAG
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
🇺🇸 Relatilmab in United States
FDA authorised Relatilmab on 18 March 2022
Marketing authorisation
Other Other approved in United States
Frequently asked questions
Is Relatilmab approved in United States?
Yes. FDA authorised it on 18 March 2022.
Who is the marketing authorisation holder for Relatilmab in United States?
BRISTOL MYERS SQUIBB holds the US marketing authorisation.